| Cardiovascular Risk Management |
1 |
1 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.99 |
| Lipids Management |
0 |
0.98 |
| Statins |
0 |
0.97 |
| LDL Cholesterol |
0 |
0.96 |
| Clinical Guidelines |
0 |
0.17 |
| Cardiovascular disease |
0 |
0.14 |
| Coronary Artery Disease (CAD) |
0 |
0.14 |
| Lipoproteins |
0 |
0.1 |
| Clinical Research |
0 |
0.07 |
| Meta-Analysis |
0 |
0.07 |
| Triglycerides |
0 |
0.07 |
| California |
0 |
0.05 |
| Insulin Resistance |
0 |
0.05 |
| Acute Coronary Syndrome |
0 |
0.04 |
| Cerebrovascular Accident |
0 |
0.03 |
| Myocardial Infarction (MI) |
0 |
0.03 |
| Type 2 Diabetes Mellitus |
0 |
0.03 |
| Europe |
0 |
0.02 |
| Fellowship |
0 |
0.02 |
| Geriatrics |
0 |
0.02 |
| Heart |
0 |
0.02 |
| Hypercholesterolemia |
0 |
0.02 |
| Infarction |
0 |
0.02 |
| Metabolism |
0 |
0.02 |
| New York |
0 |
0.02 |
| UK Site Content |
0 |
0.02 |